Key result
Adjunctive butylphthalide after IVT is linked to ~25 percentage points higher favorable 90-day prognosis.
Why the study?
Functional outcomes after intravenous thrombolysis for acute ischemic stroke remain suboptimal, and real-world evidence regarding adjunctive butylphthalide therapy combined with antiplatelet therapy is limited.
Does adjunctive butylphthalide combined with standard antiplatelet therapy improve 90-day functional prognosis in patients with acute ischemic stroke treated with intravenous thrombolysis?
Observational (n=118)
No
Does adjunctive butylphthalide combined with standard antiplatelet therapy improve 90-day functional prognosis in patients with acute ischemic stroke treated with intravenous thrombolysis?
Adjunctive butylphthalide plus standard antiplatelet therapy following intravenous thrombolysis was associated with improved 90-day functional recovery, smaller infarct volumes, and lower inflammatory/thrombotic biomarkers in acute ischemic stroke patients without increasing adverse events.
Intravenous thrombolysis (IVT) is an established treatment for acute ischemic stroke, but functional outcomes remain suboptimal, and real-world evidence regarding adjunctive butylphthalide therapy is limited. This single-center retrospective observational study evaluated the association between adjunctive butylphthalide plus antiplatelet therapy and functional recovery after IVT in 118 patients with acute ischemic stroke treated between January 2024 and December 2025. Patients were classified by post-thrombolysis treatment: 62 received butylphthalide plus standard antiplatelet therapy, and 56 received standard antiplatelet therapy alone. After propensity score matching, 52 patients were retained in each group. The primary outcome was 90-day functional prognosis, with a modified Rankin Scale score of 0-2 defined as a favorable outcome. Secondary outcomes included National Institutes of Health Stroke Scale (NIHSS) score, infarct volume, cerebral blood flow (CBF) perfusion recovery, serum high-sensitivity C-reactive protein (hs-CRP), plasma D-dimer (D-D), Barthel Index (BI) score, and adverse events. Multivariable logistic regression was used to identify factors associated with poor 90-day functional prognosis. Baseline characteristics were balanced between the matched groups (all P > 0.05). At 90 days, the butylphthalide combination group had a higher rate of favorable functional prognosis than the antiplatelet-only group (73.1% vs. 48.1%, P = 0.009). The combination group also had lower NIHSS scores, smaller infarct volumes, lower hs-CRP and D-D levels, better CBF perfusion recovery, and higher BI scores (all P < 0.05). Adverse event rates did not differ significantly between groups (P = 0.631). Multivariable analysis identified the treatment regimen as independently associated with 90-day functional prognosis (P = 0.009). Adjunctive butylphthalide plus antiplatelet therapy after IVT was associated with better 90-day functional recovery in this retrospective cohort; however, the observational design does not permit causal inference, and the safety findings are limited to the prespecified events reported here.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) conducted an observational in Acute ischemic stroke (n=118). Adjunctive butylphthalide plus standard antiplatelet therapy vs. Standard antiplatelet therapy alone was evaluated on 90-day favorable functional prognosis (modified Rankin Scale score of 0-2) (p=0.009). Adjunctive butylphthalide plus antiplatelet therapy after IVT was associated with higher 90-day favorable functional prognosis vs antiplatelets alone (73.1% vs 48.1%, P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: